MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCMSOUTH SAN FRANCISCO, Calif., ...
JOURNAVX met the primary endpoint by demonstrating statistically significant superior reduction in pain vs placebo. 1,b JOURNAVX did not meet the first key secondary endpoint that hypothesized ...
Cancer patients want to beat cancer, full stop. They want medicines to work. But they also want to thrive with fewer side effects and day-to-day disruptions. If efficacy is a top priority in cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results